-
FACO China–Japan Expert Dialogue | Professors Jin Li, Xiaotian Zhang, and Koji Kono Discuss Precision Treatment Advances in HER2-Positive Gastric Cancer
China, Japan, and other Asian countries have some of the highest rates of gastric cancer worldwide. In China, the majority of patients are still diagnosed at an advanced stage, having already lost the opportunity for curative surgery. Effective systemic therapy is therefore essential for improving survival. In recent years, innovative drugs represented by antibody–drug conjugates…
-
Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)
At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…
-
2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care
China, Japan, and South Korea have long ranked among the countries with the highest incidence of lung cancer worldwide. With a heavy disease burden, urgent unmet medical needs, and remarkably similar disease characteristics, strengthening trilateral collaboration among these East Asian nations is critical to advancing clinical oncology and addressing shared challenges in lung cancer management.
-
Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy
On November 2, 2025, world-renowned hematology experts Professor Michael R. Bishop, Director of the Cell Therapy Center at the University of Chicago, and Professor Edmund K. Waller, the Rein Saral Distinguished Chair at Emory University, visited the Peking University Institute of Hematology for an academic exchange.
-
Prof. Kun Wang: A 72-Hour Pegfilgrastim Dosing Strategy Significantly Reduces Bone Pain and Optimizes Supportive Care in Breast Cancer
Editor’s Note At the ESMO 2025 Congress, Prof. Kun Wang from Guangdong Provincial People’s Hospital delivered an oral presentation reporting results from a prospective phase III trial exploring the relationship…
-
ESMO China Voice | Prof. Guiying Xu: High Concordance of PIK3CA Mutations Between Primary and Metastatic Lesions in HR+/HER2– Breast Cancer
Editor’s Note The European Society for Medical Oncology (ESMO) 2025 Annual Congress, held in Berlin, Germany from October 17–21, gathered leading global experts to share groundbreaking advances in cancer diagnosis…
-
ESMO China Voice | Prof. Min Yan: First Data from the JS105 Study Announced — Promising Potential in PIK3CA-Mutant Populations
Editor’s Note: At the 2025 ESMO Annual Congress in Berlin, multiple innovative therapies attracted wide attention. Among them, the selective PI3K-α inhibitor JS105 released the first results from two Phase…
-
ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients
In the second-line treatment of hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer, CDK4/6 inhibitors combined with fulvestrant have become the standard of care. However, variations in efficacy and safety profiles among different inhibitors remain an important clinical consideration.
Connecting Medical Expertise through Media